Silver Sol Silver Shield For Immune Protection

Abscess, Canker Sores & Silver Shield

2010-02-19T18:02:00.000-05:00

An abscess is an open wound that exposes the blood and lymph to possible bacterial contamination, so it's vital that you use a quick wound management procedure to get the wound to heal. Apply Silver Shield immediately or as soon as possible to wash away any microbial invaders. You can then use the Silver Shield Gel with a bandage to keep it working.

If you have a large wound, you can spray the Silver Shield liquid on it or use the gel form with bandages also.

The liquid form of Silver Shield can be used in the mouth as a rinse for abscesses. Swish and hold a teaspoon of the liquid in your mouth for six (6) minutes, then swallow, so it will work internally also to fight infections. It is suggested to do this 2-3x a day for one week.

Canker sores have many causes, but an acid pH in the mouth is the most frequent problem. The soft tissue in the mouth gets destroyed by too much sugar and/or bacterial or viral infections. Silver Sol liquid can be used in the same manner as with abscesses above, repeating the process twice a day.

The herpes virus can be another cause of the problem. If the sore is accessible you can also use the Silver Shield gel by putting a dab on it several times a day. The sooner you get it on the less spreading there will be.

Buy Silver Shield at wholesale price.

Book: A Fighting Chance - 2nd Edition

2010-01-19T12:49:00.005-05:00

According to the U.S. patent (approved Nov. 2007), Silver Sol has the ability to destroy 143 types of bacteria, both forms of viruses, mold, yeast, and a limited number of parasites. It can also purify water (US Patent Office, Nov. 2006). Silver Sol can be used to treat over three hundred conditions; these are listed in the book "A Fighting Chance" by Dr. Gordon Pedersen.

Dr. Pedersen notes that Silver Sol functions as a non-toxic disinfectant for internal or external use as it comes in three forms: liquid, topical gel, and aerosolized. From toenail fungus to rashes, Silver Sol aids the immune system in reducing the bacteria, viruses, and mold it encounters.

The 2nd Edition of "A Fighting Chance" is a must have for all silver sol users. With 50 pages of new material, this book is even more informative than its predecessor. The new content includes: general uses by body system, updates to the “conditions” helped by silver, and most exciting - a compendium of studies using silver sol and their results. This book is perfect as a gift, or for anyone serious about protecting their health naturally.

It’s no secret that pathogens such as viruses, bacteria, and fungi can inflict terrible damage in the human body. Dozens of diseases—ranging from the common cold and dysentery to meningitis and pneumonia—are caused by infectious pathogens.

These diseases are all around us. We come in contact with countless bacteria everywhere we go. Bacteria are in restaurants, public restrooms, schools, airplanes—all spread by touch or passed through the air. Disease can even result from our own habits, like inadequate sleep or too much stress.

Currently, disease is winning the battle. Each year, we suffer from colds and flus. Likewise, strep throat, sinus infections, and stomachaches attack our health.

Fortunately, a simple, safe, and effective alternative exists. For decades, silver products have been marketed as a medicinal agent for use primarily as a disinfectant. In fact, patents on silver products have existed since the early 1920s. However, earlier versions of silver—called “colloidal silver”—had to be used in large amounts to be effective.

Currently, a new and vastly improved type of silver has been developed that is non-toxic and extremely effective against a wide range of bacteria, viruses, fungus, mold and other pathogens. This silver solution—called simply Silver Sol—is available both as a liquid and gel.

Because we are faced with more diseases than ever before, we need a better solution than ever before. This book outlines some of the health threats facing our modern society and what we can do to have a fighting chance in this battle.

120 pages.

Buy Silver Shield at wholesale price.
Get "A Fighting Chance" book.

Here’s a brief look at Dr Gordon Pedersen, phD, one of the world’s foremost experts on silver sol.

Doctor Pedersen has work experience with the world’s largest pharmaceutical company (Ciba/Novardis), the world’s largest sports nutrition company (Weider), dynamic biotechnology companies like Nikken, has co-authored Chicken Soup for the Enriching Soul, developed and published the mouse model for Influenza, and was an expert research and development author for Muscle and Fitness magazine.

Doctor Pedersen is an internationally renowned scientist, author, corporate officer, product formulator, and technical instructor. He formulates world-class products, expertly documents their benefits, credibly communicates through the use of scientific journals, has created international best selling scientific tools and has been a top executive for the past 11 years.

Doctor Pedersen received his doctorate degree from the Toxicology program at Utah State University where he received two distinguished service awards and constructed two space shuttle experiments. In addition, he has formulated over 160 nutritional supplements/personal care products.

He was one of the first to publish a double blind placebo controlled study on the benefits of protein supplementation in body builders, where he worked with Arnold Schwarzenegger. He was nominated to Chair the United States Pharmacopoeia Review Board (Natural Products Committee), and hosted the radio show, Common Sense Medicine with Dr. Pedersen.

Buy Silver Shield at wholesale price.
Get "A Fighting Chance" book.

Silver Shield Safety

2010-01-07T15:18:00.000-05:00

According to the Agency for Toxic Substances and Disease Registry Silver Sol is:

• Not considered to be carcinogenic.

• Completely safe for pregnant women, babies and the elderly.
• Non-toxic to the immune, cardiovascular, nervous or reproductive systems. At doses 200 times the normal adult dose, it is non-toxic to healthy human cells.

The Merck Manual shows that pure metallic silver (Silver Sol) is not categorized as a heavy metal and cannot cause argyria nor heavy metal poisoning. The salt forms of silver are poisonous.

The Physicans Desk Reference shows silver has a long history of being anti-microbial. Silver bandages are given by prescription (Silverlon) and silver has been used for over a hundred years in babies' eyes to kill bacteria after delivery. There are 44 drugs that include silver in them.

Buy Silver Shield at wholesale price.

Silver Sol and MRSA

2009-12-13T09:36:00.000-05:00

Silver Sol and The Successful Treatment of Hospital Acquired MRSA

in Human Subjects With Ongoing Infection

Gordon Pedersen, Ph.D.

Toxicologist, American Biotech Labs

Abstract
The patented form of Silver Sol (US Patent # 7135195) has been shown to destroy bacteria, viruses, and mold both in vitro and in living systems.20 Staphylococcus aureus can be completely destroyed by Silver Sol in as little as two minutes and in vitro studies show it will stay dead for 28 days. Rustum Roy Ph.D. reported that strains of methicillin-resistant Staphylococcus aureus (MRSA) could be destroyed by Silver Sol treatment in vitro.

The University of California Berkeley reports that Silver Sol can completely destroy in vitro forms of MRSA and Vancomyocin resistant Enterococcus (VRE) at levels as low as 2.5 ppm in as little as 45 to 60 minutes. With MRSA continuing to mutate and sustain resistance to antibiotics, it is encouraging to report the findings from this study, which demonstrates an all-natural opponent to this modern day plague.

This study demonstrates the benefits of Silver Sol on human subjects with serious MRSA infections of the skin. These patients were hospitalized and contracted their MRSA infections while staying in the hospital. Patients wound size, depth, and closure rates were photographed and digitized for weekly calculations that quantified the time to wound closure and overall seriousness of the infection. Before, during, and after photos demonstrate a visual accounting of the benefit of the Silver Sol treatment. All treatments were given by the hospital medical staff where patients received Silver Sol Gel sprayed topically on the wound twice daily and orally ingested 2 teaspoons of the liquid Silver Sol twice a day.

The results of this study indicate that twice-daily treatment with Silver Sol Gel (spray form) and twice-daily oral ingestion of liquid Silver Sol significantly improved treatment of hospital acquired MRSA infections in human subjects. The average time to closure improved, and patients taking Silver Sol reported a significant reduction in pain associated with the wound.

Introduction
Methicillin resistant Staphylococcus aureus (MRSA) is approaching pandemic levels and there is an immediate need for a substance like Silver Sol in controlling this potentially fatal disease. MRSA is a resistant variation of the common bacterium Staphylococcus aureus, which is resistant to a significant group of antibiotics called beta-lactams, which include penicillins and cephalosporins.1

The organism is often sub-categorized as community-associated MRSA (CA-MRSA) or healthcare associated MRSA (HA-MRSA). CA-MRSA cases were first reported in the late 1980’s. Recently, HA-MRSA has plagued the medical professionals and patients that work or live in hospitals. It is estimated that as much as 60% of hospital nurses carry MRSA in their noses and on their skin.2 MRSA could be considered to be a modern day plague because it has evolved the ability to survive treatment with most antibiotics including methicillin, dicloxacillin, nafcillin, and oxacillin.

Hospitals have a special need for help in patients with open wounds that use invasive devices, or have a weakened immune system, as these patients are at greater risk of MRSA infection. Heightened risk of infection is also seen in the hospital employees who do not follow meticulous hygiene and proper sanitizing procedures. Such employees may self-infect or transfer the contagion to patients or visitors. Indeed, a study reported by the Association for Professionals in Infection Control and Epidemiology, in 2008, concluded that the poor hygiene habits remain the principle barrier to a significant reduction in the spread of MRSA. They also indicate that this hospital risk is exponentially great when you combine the propensity for the general public to spread this superbug in public restrooms, restaurants, airplanes, nurseries, schools, athletic events, and in the home.

MRSA is progressing toward pandemic proportions. The Centers for Disease Control and Prevention (CDC), estimated that the number of MRSA infections in the US doubled in just six years from 127,000 in 1999 to 278,000 in 2005, while at the same time, deaths increased from 11,000 to more than 17,000.2 According to the Journal of the American Medical Association,3 MRSA was responsible for 94,360 serious infections and associated with 18,650 hospital-stay related deaths in the United States in 2005.

MRSA is growing out of control, and the statistics suggest grave outcomes. Liu et al reported that the annual incidence of CA-MRSA in San Francisco residents during 2004-2005 was 316 cases per 100,000 population, while the annual incidence of HA-MRSA was 31 cases per 100,000 population.4 Noskin et al reported that MRSA patients had, on average, three times longer stays (14.3 days versus 4.5 days), incurred three times the expenditure ($48,824 versus $14,141), and experienced five times the risk of in-hospital death (11.2% versus 2.3%) as compared to patients without this infection.5 Whilst Wyllie et al reported that 34% of patients with MRSA died within 30 days of infection.6 Wyllie also reported that the most common sites of infection were the nostrils, respiratory tract, open wounds, intravenous catheters, and urinary tract.

Hospitals in Denmark, Finland, the Netherlands,7 and VA hospitals in Pittsburg report that MRSA infections can be significantly reduced using sanitary methods that include swabbing the nostrils and hands with antibacterial protection. These studies demonstrate the potential benefits of an antibacterial agent used prophylactically on the hands and nostrils as long as resistance is not a potential long term problem.

MRSA is a resistant staphylococcus infection that usually presents as a patch of small pus surrounded by redness and swelling, and resembles pimples, spider bites, or boils. Infection may or may not be accompanied by a fever and rash. The bumps become larger and spread, and larger, painful, pus-filled boils can develop deep into the tissue. Approximately 75% of CA-MRSA infections are localized to the skin and soft tissue, however a minority of these infections spread and affect vital organs, causing sepsis, toxic shock syndrome, and flesh eating (necrotizing) pneumonia.8

At present, it is not fully understood why some healthy people survive MRSA infections and others do not.

The current treatments of MRSA include vancomycin and teicoplanin, which are prescription antibiotics categorized as glycopeptides.9 The absorption of these antibiotics is very poor and they must be given intravenously in order to control systemic infections.10 However, there are several new strains of MRSA that have become resistant even to vancomycin and teiocplanin.11,12 At present, linezolid, quinupristin/dalfopristin, daptomycin and tigecycline are used to treat more severe infections that do not respond to glycopeptides such as vancomycin.13

In addition, oral treatments include linezolid, rifampicin and fusidic acid, rifampicin and fluoroquinolone, pristinamycin, cotrimoxazole, doxycycline or minicycline and clindamycin. Nature14 reported that a new antibiotic called platensimycin has demonstrated MRSA activity.15,16 It should be noted that some of the newest drug discoveries can cost $1600 per day, which may prohibit their ubiquitous distribution.

The spread of MRSA is complicated by the fact that hospitals discharge contagious patients into the community, workforce, schools, and general public.17 In the US, it is estimated that 95 million people carry Staphylococcus aureus in their noses, of these 2.5 million carry MRSA,21 and 23% of these require hospitalization.22 MRSA is nearing pandemic proportions and there is a serious need for a daily use antibacterial that does not produce resistant strains of MRSA.

Currently, Silver Sol may be the only prophylactic use product that has activity against MRSA, and that could be used for prevention as well as treatment of MRSA because it does not produce resistant strains.

Materials and Methods

AHS is a hospital-based elderly health care provider that approved the study of 308 subjects in their elderly care (nursing home) hospitals. The patients were admitted to the hospital without MRSA, but had acquired the MRSA infection while in hospital and the skin infections were ongoing for over one year.

The Medical staff treated and photographed the wounds before any Silver Sol treatment and every week during the treatment. The size and depth of the wounds were measured in centimeters and recorded weekly by the hospital staff. Silver Sol Gel was sprayed (using a hand operated pump spray) on the wounds topically twice a day. Patients answered a questionnaire regarding their wellness, including pain evaluations.

Results
Tables 1, 2, and 3 illustrate significant improvement in the ability of Silver Sol to close a wound and improve the time to wound closure.

Table 1. Percent Wound Closure in HA-MRSA Patients (ongoing 1 year)
% Closed Week 1 Week 2 Week 3 Week 4 Week 5
100 98% 100%
90 97% XXX XXX
80 95% XXX XXX XXX
70 XXX XXX XXX XXX
60 67% XXX XXX XXX XXX
50 XXX XXX XXX XXX XXX
40 XXX XXX XXX XXX XXX
30 XXX XXX XXX XXX XXX
20 XXX XXX XXX XXX XXX
10 XXX XXX XXX XXX XXX
0 XXX XXX XXX XXX XXX

Table 2. Average Wound Size in Centimeters in HA-MRSA Patients
Week 0 Week 1 Week 2 Week 3 Week 4 Week 5
0.25 cm 0.15cm 0.10 cm 0.10 cm 0.10 cm 0.0 cm

Table 3. Summary of Data
Week Size of Wound (cm) % Wound closure
0 0.25 cm 0%
1 0.15 cm 67%
2 0.10 cm 95%
3 0.10 cm 37%
4 0.10 cm 98%
5 0.0 cm 100%

Concluding Remarks
The results of this study strongly suggest that Silver Sol Liquid and Gel demonstrate the ability to destroy HA-MRSA and significantly improve healing outcomes. The results indicate that wounds close as much as three times faster than wounds not treated with Silver Sol, thus quantifying the benefits of Silver Sol. HA-MRSA can be fatal and cause serious infections – even when treated with antibiotics – yet, Silver Sol Gel and Liquid demonstrate improved wound treatment and improved time to wound closure in human subjects.

The improvements in wound healing, as identified by a shorter time to wound closure, suggests that there is an improvement in immune function due to the fact that Silver Sol reduces the bacteria in the wound. By reducing the bacterial infection wound healing improves by approximately three times and reduces pain in the process.

This reduction in pain and improvement to healing can be attributed to the fact that infection, inflammation, and tissue damage are reduced when using Silver Sol, and suggests that there are several beneficial mechanisms of action at work. The fact that there are wounds in this study that are large enough to be difficult or impossible to close on their own, and yet when Silver Sol is used the wounds heal completely, suggest the possibility that stem cell activation is being produced.

By observing the healing results published in this study, it is evident that this remarkable and bactericidal liquid and gel should be considered to be leaders in the defense against HA MRSA.

The improvements demonstrated here suggest that Silver Sol can help improve healing times, which could potentially reduce the overall cost of treatment by as much as three times and reduce the average length of stay in a hospital. This study demonstrates the benefits of Silver Sol in reducing the infectious nature of a skin born disease acquired in a hospital. In today’s world of mutating bacteria and antibiotic resistant infections producing potentially fatal disease, Silver Sol could be the health vector that helps reduce the health risk to all patients, staff and visitors in the hospital. Buy Silver Shield at wholesale price.

References
1. Okuma K, Iwakawa K, Turnidge J, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40:4289–4294. doi:10.1128/JCM.40.11.
2. Klein E, Smith DL, Laxminarayan R. Hospitalizations and Deaths Caused by Methicillin- Resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840– 1846.
3. Zeller JL, Burke AE, Glass RM. MRSA Infections. JAMA. 2007;298:1826.
4. Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004- 2005. Clin Infect Dis. 2008;46:1637-1646.
5. Noskin GA, Rubin RJ,Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmen E. The Burden of Staphylococcus aureus Infections on Hospitals in the United States: An Analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med. 2005;165:1756–1761. doi:10.1001/archinte.165.15.1756.
6. Wyllie D, Crook D, Peto T. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997–2003: cohort study. BMJ 2006;333:281. doi:10.1136/bmj.38834.421713.2F.
7. McCaughey B. Unnecessary Deaths: The Human and Financial Costs of Hospital Infections. 2nd ed. Available at: http://www.tufts.edu/med/apua/Patients/ridbooklet.pdf. Accessed February 22, 2009.
8. MRSA Toxin Acquitted: Study Clears Suspected Key to Severe Bacterial Illness [news release]. National Institute of Health; November 6, 2006. Available at: http://www3.niaid.nih.gov/news/newsreleases/2006/staphtoxin.htm. Accessed February 22, 2009.
9. Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, Cumbo TJ. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis. 1998;26: 1204-1214. doi:10.1086/520287. 299
10. Janknegt R. The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic, and pharmacoeconomic considerations. Pharm World Sci. 1997;19:133-141. doi:10.1023/A:1008609718457.
11. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 1997;179: 2557-2566.
12. Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect. 2006;12 (Suppl 1):3-8.
13. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-associated methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37:1050-1058. doi:10.1086/378277.
14. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate use program. Clin Infect Dis. 2003;36:159-168. doi:10.1086/345744.
15. Bayston R, Ashraf W, Smith T. Triclosan resistance in methicillin-resistant Staphylococcus aureus expressed as small colony variants: a novel mode of evasion of susceptibility to antiseptics. J Antimicrob Chemother. 2007;59:848-853. doi:10.1093/jac/dkm031.
16. Wang J. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006;441:358-361.
17. Cooper BS, Medley GF, Stone SP, et al.. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. PNAS. 2004;101:10223-10228. doi:10.1073/pnas.0401324101.
18. Graham P, Lin S, Larson E. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006;144:318-325.
19. Jernigan JA, Arnold K, Heilpern K, Kainer M, Woods C, Hughes JM. Methicillin-resistant Staphylococcus aureus as community pathogen [conference summary]. Emerg Infect Dis [serial on the Internet]. 2006 Nov. Available from http://www.cdc.gov/ncidod/EID/vol12no11/06-0911.htm. Accessed February 22, 2009.
20. Treatment of humans with colloidal silver composition. US patent 7 135 195. November, 2006.

About The Author
Dr. Gordon Pedersen received his Doctorate degree in Toxicology with emphasis in Virology from Utah State University and a Master's degree in Cardiac Rehabilitation and Wellness.

Dr. Pedersen has authored a number of important protocols in virology. He is the formulator of more than 150 nutritional products, an international best-selling author, and host of the radio show "Common Sense Medicine". He now serves as the Director of the Institute of Alternative Medicine and was nominated to chair the United States Pharmacopoeia Review Board, Natural Products Committee. Buy Silver Shield at wholesale price.

Silver Sol and Homeland Security

2009-11-10T10:27:00.007-05:00

Silver Patent Analysis

(U.S. Patent No. 7,135,195)

Silver Shield helps eliminate the following:

• Bacillus Anthracis–Anthrax
• Candida Albicans–Yeast
• YersiniaPestis–Bubonic Plague
• MRSA –Resistant Staph Aureus
• MycobacteriaBovisand TB –Tuberculosis
• Salmonella -Food Poisoning
• Fungal infections of the skin
• Bacterial infections of the skin
• Vaginal & urinary tract infections
• Respiratory & nasal infections
• Conjunctivitis –pink eye

SILVER SHIELD: REVOLUTIONARY SILVER FOR THE BODY!

From a lecture by Dr. Gordon Pedersen (Ph.D. in toxicology with a Master's degree in Wellness)

This special patented colloidal silver worked in 1.2 minutes against the bubonic plague. In the lab they used 160x more plague cells than normal and it killed off 99.9%. This plague killed off over 1/3 of the entire population of Europe. We are going to have modern day plagues ... and we suffer a modern day plague now with MRSA (staph infections). Antibiotics are not helping and people are dying.

This substance has been presented to Homeland Security by Senator Orrin Hatch. General P.K. Carlton, MD, the Director of Integrative Center for Homeland Security has stated in written form:

"I would like to bring to your attention a resource that I feel can be used and utilized in the area of bio-defense from bio-terrorism to infectious diseases such as SARS. The ABL antimicrobial has undergone rigorous testing and has been found to kill anthrax, bubonic plague, hospital staph and SARS. It's the first new antimicrobial for the hospital in many years. In addition the product is non-toxic to humans, this product is EPA approved for hospital staph and bubonic plague and currently awaiting section 18 approval for anthrax. In short, we currently do not have anything with such a wide spectrum of efficacy in our inventory. As such, I recommend that the antimicrobial be evaluated for addition to the national pushback stockpile."

How does silver work? It disables the enzyme that one-celled bacteria, viruses, and fungi need for oxygen metabolism. In the presence of silver, these pathogenic microbes suffocate. Dr. Pederson in his book, "A Fighting Chance – How to Win the War Against Bacteria, Viruses & Mold With Silver," on page 13 states, “Silver Sol is an Ag 404 which means that it is missing two electrons in its outer shell. This means that a Silver Sol has catalytic capabilities. Catalytic means that while one electron is destroying bacteria viruses and mold, the other is being recharged. This catalytic conversion allows the Silver Sol to destroy then instantaneously recharge and: kill: again and again – like a rapid fire machine gun. The result is that Silver Sol can destroy thousands of times more pathogens than a simple colloid or ionic silver. This means that Silver Sol can be much more effective at a very safe concentration (5-20 parts per million), which can be potentially consumed every day.”

In one powerful experiment, 50 gallons of raw sewage were pumped into a pool without any disinfectant. The E. coli count (a standard measure of contamination) was at 7,000 E. coli cells per milliliter of water. The water was exposed to silver electrodes and within three hours, all 50 gallons were free of E. coli.

Silver Shield Colloidal silver is an effective ally in the fight against over 650 disease-causing organisms. These include: bacteria (typhoid, diphtheria, certain types of food poisoning, and pneumonia); viruses (the common cold, influenza, and measles); protozoa (malaria, giardiasis, amebic dysentery); fungi (ringworm, thrush, candida albicans, and athlete's foot); rickettsiae (rocky mountain spotted fever and Q fever); and chlamydiae (infections of the eye, the genitals, and the respiratory system). There is no known microbe that colloidal silver does not destroy.

Silver, however, doesn't destroy beneficial enzymes because they are very different from the enzymes of single-celled life which silver targets. Silver is nontoxic. Also, colloidal silver doesn't interact or interfere with other medicine being taken.

“Based on my research, I have found the new silver solution to be a safe and effective weapon against harmful yeasts, viruses, and bacteria. Its low concentration, high effectiveness, and lack of side effects make it an ideal supplement for the prevention and care of conditions associated with these pathogens.” Kenneth Friedman, Ph.D. (MIT), M.S. (MIT & Harvard)

“To date, there are no potentially pathogenic bacteria tested that...[this] product has not killed.” Dr. R. Leavitt, Professor of Molecular Biology and Microbiology Brigham Young University

View lots of research, a video and other information on this at Silver Shield-Silver Sol website or purchase Silver Shield at wholesale prices.

This website is maintained by TheHerbsPlace.com.

For herbs, supplements, and essential oils guaranteed for purity, shop The Herbs Place - wholesale prices & fast shipping from 4 warehouses. What's On Sale Now?

Silver Fights The Germ War

2009-10-26T19:45:00.000-04:00

Antibiotics are becoming more potent and dangerous as their failure rate increases. They are also the cause of new strains of superbugs, like MRSA. Health care costs are rocketing out of control and bioterrorism is a real threat. We've stocked up on this item because of it's effective for many health ailments.

With a variety of viral flu outbreaks, e-coli contamination, and a host of other potential pandemics that create a strain on health in America, the new Silver Shield solution and gel offers a fighting chance in germ warfare.

"Silver has undergone rigorous testing and has been found to kill anthrax, bubonic plague, hospital staph and SARS. This product is EPA approved ... In short, we currently do not have anything with such a wide spectrum of efficacy in our inventory." General P.K. Carlton, M.D., Director of Integrative Center for Homeland Security

How Does Silver Sol Kill Bacteria?

Silver Sol ions are available to act against contaminating bacteria in four (4) ways:

• Silver Shield ions combine with bacterial proteins in the cell and cell wall.

• Silver Shield ions interfere with DNA replication by acting like a magnet that attracts charged DNA particles. The DNA binds so tightly to the silver that it makes a chaotic tangle of incomplete genetic material. This inactivates the virus and blocks replication of it. Normal cells are protected by a thicker cell membrane containing a balanced charge.

• Silver Shield ions promote formation of reactive oxygen species (ROS), thus helping the body rid itself of toxins and foreign invaders through oxidation.

• Silver Shield ions resonate at a frequency selectively destructive to pathogens. In fact, it has been measured to resonate at 890 to 910 terahertz. This is the same frequency at which germicidal ultraviolet light resonates. The tiny silver particles are absorbed into the red blood cells at the perfect frequency to destroy bacteria, viruses, fungus and yeast.

Silver Shield provides a simpler and more economical solution for many health issues besides fighting any invaders that would challenge your immune system.

Silver products have been used safely as antimicrobial agents for many years. Silver is mentioned in the Egyptian writings. Greek and Romans used silver vessels for water purification. In the early plagues, the wealthy used silverware to protect themselves.

Doctors have used silver sutures in surgical wounds and to combat wound infections during WWI. Silver is used widely in hospitals and even commercial airlines use silver water filters. Silver Shield Gel has been FDA approved for treatment of wounds and burns.

Not all silver is alike, so it's important to know what to look for in colloidal silver. There is now technology that makes it safe and non-toxic. The product, Silver Shield, has EPA designation as non-toxic (EPA# K043106) and a US patent (#7,135,195) for safe technology. The fine particle-size colloids ensure maximum efficiency.

Silver Shield has a long shelf life and is a great item to include in your emergency preparedness supplies. With winter on our heels, it's time to get prepared for the first signs of colds and flu so you can ward off any real symptoms and lost work and living time. Buy Silver Shield at wholesale price.

Silver Shield Researched and Approved

2009-10-06T22:25:00.007-04:00

Silver sol technology keeps your immune system strong daily. Make it your first line of microbial defense. Silver Shield with patented silver sol technology is:

• EPA designated as non-toxic (EPA# K043106)

• U.S. patent for safe technology (Patent # 7135195)

• FDA approval on the Silver Sol Gel

• Doctor recommended

• Backed by science

• Proven safe in 7 different safety studies

• GSA and VA approved for purchase

• Tested by major universities and certified independent laboratories

• Hundreds of completed tests at government certified laboratories

• Pro-biotic tested and found harmless against friendly bacteria or flora

• Customer proven with over a million bottles sold throughout the world

• Only product of this type to be presented before a congressional hearing on Malaria (Apr 2005)

Buy Silver Shield at wholesale price.

Video: Dr. Pedersen Speaks On Silver Sol Silver Shield

2009-10-01T02:00:00.001-04:00

Buy Silver Shield at wholesale price.

Research Studies on Silver Shield

2009-09-30T13:10:00.001-04:00

Silver Shield provides a first line of defense to protect our bodies against pathogens that are killing millions of people throughout the world annually. The Silver Solution is an immune-modulator, meaning that it can help a healthy immune system to fight off disease!

Safety Studies

1) NAMSA - Toxicity Tests - found non-toxic at up to 200 times the normal adult dosage.

2) Brigham Young University (Jessica K. Pate, 08/04) - Probiotic Bacteria Study - found that it did not kill probiotic bacteria.

3) Viridis BioPharma - Probiotic Bacteria Study - found that it did not kill probiotic bacteria.

4) Sheri C. Patel Research Centre - Found non-toxic in injection mouse model tests at up to 50 mg/kg (10 ppm).

5) Sheri C. Patel Research Centre - Found non-toxic in oral mouse model tests at up to 5000 mg/kg (32 ppm).

6) Sheri C. Patel Research Centre - Found non-toxic in injected mouse model tests at up to 5000 mg/kg (32 ppm).

7) Viridis BioPharma - Cytotoxicity Study - found non-cytotoxic in human hep2 cell line and also found non-cytotoxic in a Vero cell line (African Green Monkey).

8) Northview Pacific Labs - (13 December,2004) up to 32 ppm Skin irritation tests - The product found non-irritating to the skin.

Human Studies

Four human clinical trial studies in four different hospitals have been completed to date, including 124 patients.

The studies were designed to test the oral use of the product (at 10 ppm) to treat 18 different human ailments and diseases. In these studies there were no failures, and almost all patients were deemed as fully recovered in less than one week.

The studies included ailments such as: upper respiratory tract infections, eye infections, ear infections, urinary tract infections, sore throats, abdominal pain and diarrhea, bronchitis, vaginal yeast infections, external cuts, gonorrhea, pelvic inflammatory disease, various mouth problems, retro viral infections, Malaria, etc. The product was found to be so effective that the country of Ghana approved the product as an antibiotic-alternative drug.

Malaria Testing

The first two human studies looked at Malaria along with 17 other ailments. The second two studies were focused on just the treatment of Malaria following a standard protocol.

To date 54 Malaria patients have officially been treated with the 10 ppm Silver Solution. The ages of the patients involved in the studies have ranged from just one year to 90 years old. Both male and female patients were treated. On average just one ounce of the silver solution was used [in some cases as little as ½ an ounce] daily.

On average full recovery was obtained in 5 days. The shortest recovery times were about 2 days and the longest reported recovery time was about 10 days. A number of the cases were complicated by the fact that the patients were also suffering from other ailments including urinary tract infections, measles and fungal infections and this may have contributed to the increased treatment times.

There were no failures in the testing, all patients achieved full recovery in an average of five days.

Yeast Testing

1) University Of California at Davis (Jason Henrie, 4/13/99) - Yeast Test - found effective in killing S. cerevisiae var and Montrachet forms of yeast.

2) Brigham Young University- Antimicrobial Efficacy Against Vaginal Pathogens When Used As A Suppository - found effective in killing 21 pathogens, including two different types of yeast and one other fungus. Jessica K. Pate, August 2004.

3) Viridis BioPharma (India) - found effective in killing Candida albicans.

4) Analytical Resource Laboratory - found effective at killing Candida albicans.

Silver Shield vs. Bacteria

1) Brigham Young University - Antibiotic Comparison - found more effective and more broad-spectrum than any of the individual antibiotics tested (15 pathogens).

2) Brigham Young University - Activity Against Numerous Pathogenic Bacterium - found effective at killing every pathogenic bacterium it was tested against at less than 10 ppm (17 pathogens).

3) Analytical Resource Laboratory - Rapid Challenge Tests - found effective at killing the MRSA bacterium.

4) Nelson Laboratories, Inc. - Antibacterial Tests - found effective at killing P. aeruginosa, S. Aureus, S. Choleraesuis (120 individual bacterial tests).

5) Nelson Laboratories, Inc. - EPA Tests - found effective at killing P. aeruginosa, S. Aureus, S. Choleraesuis (1620 individual bacterial tests).

6) Nelson Laboratories, Inc. - Tuberculocidal Kill Time Study- 97.3% kill in 45 minutes.

7) Brigham Young University - Sporicidal Activity Bacillus subtilis (anthrax test)- 98.8% kill in 4 hours.

8) Nelson Laboratories, Inc. - Sporicidal Activity Clostridium sporogenes (anthrax test) eliminated all spores in 8 hour study.

9) Brigham Young University - Sporicidal Activity Bacillus subtilis (anthrax Test) - 6 log reduction in 5.02 hours.

10) Illinois Institute Of Technology - Sporicidal Study B. anthracis- 99% kill at 6 hours.

11) Nelson Laboratories, Inc. - Sporicidal Activity (Anthrax AOAC Test) - passed for both Clostridium sporogenes and Bacillus subtilis at 10 hours.

12) Illinois Institute Of Technology - Sporicidal Study (Anthrax AOAC Test) - passed for Clostridium sporogenes at 8 hours.

13) Brigham Young University - Bactericidal Activity Against Y. pestis (Bubonic Plague) (Richard A. Robinson PH.D., 07/08/03)- 10 ppm 99.77% kill in 2 minutes/ 32 ppm greater than a 6 log reduction in less than 2 minutes.

14) Central Utah Water - Bacteria Kill In Water Treatment - killed all bacteria listed as TNTC in raw river water at a dilution of 1/100 (0.10 ppm) in 1.5 minutes of contact time.

15) Central Utah Water - Bacteria Kill In Water Treatment - killed all bacteria listed as TNTC in raw river water at a dilution of 1/200 (0.05 ppm) in 20 minutes of contact time.

16) Grant H. Layton D.D.S. - Dental Unit Water Line Bacteria Biofilm Study - found effective in killing all biofilm and maintaining water purity at a level of 0.50 ppm.

17) Viridis BioPharma - Antimicrobial Tests - found effective at killing 12 pathogens including: MRSA 1, MRSA 2 and Candida albicans.

18) Central Utah Water (Don G. Yates 10/18/04) – Recheck - Bacteria Kill In Water Treatment- killed all bacteria listed as TNTC in raw river water at a dilution of 1/100 (0.10 ppm) in a number of different time frames using both the 10 and 32 products.

Silver Shield Vs. Viruses

1) Viridis BioPharma - Bacteriophage viral model - killed a billion virus in 2.5 hours.

2) Viridis BioPharma - Viricidal Activity against Hepatitis B Virus - found effective in both DNA Polymerase and Reverse Transcriptase inhibition. This test is currently in Peer Review.

3) Haffkine Institute (Dr. R.A. Deshmukh, 12/05/03) - Viricidal Activity against Hepatitis B Virus - found effective in both DNA Polymerase and Reverse Transcriptase inhibition.

4) U.S. National Institute Of Health - SARS Kill Test - 99% Reduction in 60 minutes.

5) Viridis BioPharma - Viricidal Activity against Hep B Virus - Found to be at least twice as effective as a major drug in the Reverse Transcriptase inhibition.

6) Viridis BioPharma- (June, 2005) Full report on SilDustl 100 wound sprinkling powder. The test work includes antimicrobial testing against a viral challenge. The product is designed as a timed-release antimicrobial product. The product was found to kill the virus in three hours.

7) ATS- (November, 2005) Avian Influenza A Reassortant H3-N2 - Both 10 and 32 ppm - Killed 96.8 and 99.0% respectively in 2 hours. No virus found with either 10 or 32 ppm product at 12 hours.

8) ATS- (November, 2005) Beijing Influenza A H1-N1 - Both 10 and 32 ppm - Killed 98.2 and 99.9 % respectively in 2 hours. No virus found with either 10 or 32 ppm product at 12 hours.

9) Utah State University- NIH Lab (April, 2006) Avian Influenza A H5-N1 Vietnam Hybrid- 10 ppm reduced the virus to below detectable levels in 6 hours.

Silver Shield vs. Avian Influenza (H5N1)
Executive Summary by Dr. Gordon Pedersen

There is a need to find a preventive therapy against the fatal virus H5N1 Avian Influenza. In the spring of 2006, Dr. Sidwell and The Institute for Antiviral Research was commissioned to test the Silver Shield 10ppm in vitro against Avian Influenza. Results from that study found that it is effective against the virus when tested in the lab. The following report is from the follow-up study on Avian Influenza H5N1 which was performed on mice. This report gives a determination of the level that the Silver Shield can help prevent death and disease from Avian Influenza H5N1.

H5N1 Experiment

The purpose of this experiment was to determine the silver solution’s potential for preventing Avian Influenza (the Bird Flu-H5N1) in a living model.

The experimental design included 19 mice per treatment group. The mice were treated with the silver solution twice daily for 28 continuous days. The mice were infected with Avian Influenza H5N1 on day 7, and the results were compared to those found in the infected placebo group.

Results of H5N1 Experiment

Survival:
60% of the infected mice treated with the silver solution survived.

30% of the placebo-treated, infected mice survived. This is a 100% improvement in the ability to survive a fatal H5N1 viral infection. This demonstrates how the silver solution provides twice as much prevention against H5N1 influenza when compared to non-treated mice.

This data strongly suggest that the disease is being inhibited and treated. In addition, there were improvements found in the lung scores, lung weights, virus found in the lungs and oxygen circulating in the blood.

Oxygen saturation in the blood

The infected mice treated with the silver solution had a greater oxygen saturation at day 11, than the placebo-treated infected mice. This suggests that the silver solution increased the ability to transfer vital oxygen throughout the body, even when the mice were at the most vulnerable time in the study.

Toxicology Controls

Mice were given a ten times normal dose of 10ppm silver solution. This resulted in 100% of the mice surviving and even thriving. This group of mice, were given extremely high doses of silver solution to determine if very large doses would be toxic. 100% of these mice survived, and even gained weight, demonstrating the safety of the product.

Summary

Silver Shield safely helps prevent death from H5N1 Bird Flu infection, improves oxygen transfer and reduces the severity of the infection.

Silver Shield Vs. Other Microbes

1) Analytical Resource Laboratory - Rapid Challenge Test - found effective at killing Trichomonas vaginalis.

2) Four hospitals in Ghana, West Africa - 3 Human Studies Against Malaria Etc. - found effective in killing the Malaria protozoa and eliminating it from the bloodstream within an average of 3.43 days (study number three).

3) Viridis BioPharma (22 July, 2005) - Malaria trial animal model (Plasmodium berghei) interim report. (10 ppm) Found to have a 94.3% inhibition rate.

4) William Beaumont Army Medical Center (2005) - In Vitro activity against Leishmania Promastigotes. Killed all three types at between 1-2 ppm.

Antibiotic/Silver Shield Combinations

1) Viridis BioPharma- Antibiotic Symbiotic Relationship Study - Found to have a very high symbiotic relationship in killing MRSA etc. with two different antibiotics. Found to be much more effective than either of the antibiotics separately.

2) Viridis BioPharma - Bacterial Activity Of Combinations Of NSS With 19 Antibiotics Against 7 Organisms. Feb 2005. Found to have a synergistic or additive effect with all 18 antibiotics tested.

Other Silver Solution Tests

1) 1000 bottle burn treatment study (Summit Cancer Clinic) - found effective in the treatment of radiation burns at just 10 ppm.

2) FDA burn studies, (Viridis BioPharama) studies for FDA approval, including comparisons to pharmaceutical products - found to be 10 times more effective at killing the MRSA bacterium than a leading pharmaceutical product, even though the leading pharmaceutical product contained over 300 times more of the active ingredient (silver) than the Silver Sol product.

3) Kansas State University - Food disinfection tests (used on beef) - found safe and effective in the killing of bacterium on beef carcasses.

4) A & L Southern Agricultural Laboratories - found effective against Xanthomonas campestris pv. Vesicatoria, plant pathogen.

5) University Of Florida - Pesticide Efficacy Trials For Ornamental Plant Diseases - found to reduce disease leaf spots.

6) Brigham Young University (Jessica K. Pate, 04/04) - Antimicrobial Activity Of Dry 32 ppm on Impregnated Surgical Mask Material- even after the product was dried on the mesh material, the product was found effective at killing bacteria pulled into the mask material.

7) Brigham Young University (Jessica K. Pate, 08/04) - Antimicrobial Activity Of 32 ppm In A Soap Solution - found to be a highly effective antimicrobial even when the product was diluted down to just 5.6 ppm, in a soap matrix. In the test work, the nano-silver product/soap mix, killed 21 pathogenic bacterium, 2 different yeasts, and Trichophyton rubrum (athlete’s foot, jock itch, ringworm).

8) Brigham Young University - Increased Efficacy Of Povidone Iodine 10% Solution When Combined With 32 ppm - found to have a synergistic relationship in disinfection.

9) Penn State, Arizona State, University Of Arizona, Study Of The NSS product. Unique Properties Of this Silver Sol Technology- found to have very unique properties, which are not found in other silver products. This information has been filed for patent.

10) Viridis BioPharma - (June, 2005) Full report on SilDustl 100 wound sprinkling powder. The test work includes antimicrobial testing against three (MDR) Multi Drug Resistant strains of bacteria and one viral challenge. The product is designed as a timed-release antimicrobial product. The product was found to kill the MDR bacteria in minutes and the virus in three hours.

11) Viridis BioPharma - (June, 2005) Full report on treating Multi Drug Resistant (MDR) and Multi Co-therapy Resistant (MCR) mutants using engineered nano silver particle.

12) Viridis BioPharma - (June, 2005) Full report on Prevention of Gentamicin Resistant Mutants by closing Mutant Selection Window (MSW) with engineered nano silver particle.

New Patents

The New Silver Solution product is the only patented engineered nano-silver particle product in the United States. Two U.S. construction patents have been issued. The unique SilverSol Technology(TM) now has a patented construction process [U.S.Patent #6214299], patented particle sizes and many patented end uses [U.S.Patent #7135195]. This patent covers a wide range of pathogens, including: Anthrax and the bacteria that cause Bubonic plague; and Viruses such as Hepatitis B and HIV; and, Parasitic diseases such as Malaria. The patent also includes more common infectious agents and ailments including MRSA , TB, skin infections, ear and eye infections, upper respiratory tract infections, STD's, and others.

Buy Silver Shield at wholesale price.

Effectiveness Of Silver Shield

2009-09-29T15:27:00.001-04:00

A. Purpose of Example

The purpose of this example is to demonstrate the utility of silver-based composition embodiments of the present invention for treating a variety of human ailments. The studies in this section were performed in Ghana, West Africa, at the Air Force Station Hospital under the direction of Dr. Kwabiah, at the Korie-Bu Teaching Hospital under the direction of Sr. Sackey, and at the Justab Clinic/Maternity Hospital under the direction of Dr. Abraham.

In total, fifty-eight (58) patients were treated using a composition of the present invention comprising 10 ppm silver. The composition was used both internally and externally as an alternative to traditional antibiotics.

The ailments treated included malaria, upper respiratory tract infections, urinary tract infections, sinusitis, vaginal yeast infections, eye, nose and ear infections, cuts, fungal skin infections, and sexually transmitted diseases, such as gonorrhea.

B. Treatment Methods and Outcomes

Abdominal pain and Diarrhea. The method comprises the step of administering approximately 5 25 ml of silver composition, one to five times a day orally until there was a response. One patient was treated with about 10 ml (about two teaspoons) of a composition of the present invention three times in one day. The patient had a full recovery in one day.

Bronchitis. The method comprises the step of administering 2-25 ml of silver composition orally, one to five times a day until there was a response. Two patients were treated with about 5 ml (about one teaspoon) each of a composition of the present invention for two times a day for three days. The patients had a full recovery in three days.

Vaginal Yeast (Candida). The method comprises the step of administering 5-25 ml of silver composition, one to five times a day as vaginal douches until there was a response. Five patients were treated with about 10 ml (about two teaspoons) each of a composition of the present invention for two times per day. The patients showed a full recovery within six days.

Conjunctivitis. The method comprises the step of administering several drops of a silver composition, one to five times a day to the infected eye until there was a response. Two patients were treated with several drops of a composition of the present invention in each of the infected eyes for two times per day. The patients had a full recovery after one day.

External cuts and infection (including Staphylococcus skin infections, septic ulcers and infected abscesses). The method comprises the step of administering a silver composition, one to five times a day to the infected area until there was a response. Six patients were treated with about 5 ml (about one teaspoon) each of a composition of the present invention on the infected areas for two times per day. The patients showed a full recovery within three days.

External Otitis. The method comprises the step of administering a silver composition, one to five times a day to the infected ear until there was a response. Six patients were treated with approximately two drops of a composition of the present invention into the infected ears for three times per day. The patients showed a full recovery after about four days.

Otitis Media. The method comprises the step of administering a silver composition, one to five times a day to the infected ear until there was a response. One patient was treated with approximately two drops of a composition of the present invention comprising into the infected ear three times per day. The patient showed a full recovery in four days.

Fungal Skin Infection. The method comprises the step of administering a silver composition, one to five times a day topically to the infected area until there was a response. Two patients were treated with about ten ml (two teaspoons) each of a composition of the present invention three times per day. The patients showed a full recovery within eight days.

Gonorrhea. The method comprises the step of administering a silver composition to the infected area until there was a response. Two patients were each treated with about ten ml (two teaspoons) of a composition of the present invention three times per day. The patients showed an absence of symptoms within six days.

Malaria. The method comprises the step of administering a silver composition, one to five times a day orally to the patient until there was a response. Eleven patients were treated with about ten ml (two teaspoons) each of a composition of the present invention three times per day. The patients showed a resolution of symptoms within five days.

Halitosis and Gingivitis. The method comprises the step of administering a silver composition, one to five times a day as a mouthwash until there was a response. Two patients were each treated with the composition as a mouthwash. There was a full resolution of symptoms within three days (gingivitis) and within one day (halitosis).

Pelvic Inflammatory Disease. The method comprises the step of administering about 5 25 ml of silver composition, one to five times a day as a vaginal douche until there was a response. One patient was treated with about 5 ml (approximately one teaspoon) of a composition of the present invention two times per day. The patient's symptoms resolved within five days.

Pharyngitis. The method comprises the step of administering a silver composition, one to five times a day as a gargle until there was a response. Four patients were each treated with about ten ml (two teaspoons) of a composition of the present invention three times per day. The patients showed full recovery within six days.

Retrovirus Infection (HIV). The method comprises the step of administering a silver composition, comprising 5 to 40 ppm silver one to five times a day orally area until there was a response. One patient exhibiting HIV (human immunodeficiency virus )was treated with about 5 ml (approximately one teaspoon) of a composition of the present invention two times per day. The patient's symptoms resolved within five days.

Sinusitis and Rhinitis. The method comprises the step of administering a silver composition, one to five times a day to the nose until there was a response. Six patients with nasal infections (four with sinusitis and two with rhinitis) were each treated with approximately two drops of a composition of the present invention comprising in their nasal passages three times per day. The patients showed full recovery within four days.

Tonsillitis. The method comprises the step of administering a silver composition, one to five times a day as a gargle until there was a response. One patient was treated with a composition of the present invention three times per day. The patient showed full recovery within seven days.

Upper Respiratory Tract Infection. The method comprises the step of administering a silver composition, one to five times a day orally until there was a response. Two patients were each treated with about 5 ml (approximately one teaspoon) of a composition of the present invention three times per day. The patients showed full recovery within six days.

Urinary Tract Infections. The method comprises the step of administering a silver composition, one to five times a day orally until there was a response. Three patients were each treated with about ten ml (two teaspoons) of a composition of the present invention two to three times per day. The patients showed full recovery within six days.

C. Discussion

These results are consistent with the various in vitro tests reported herein. Essentially, the silver composition is extremely effective against a large number of microbes in vitro. However, the tests indicate that this effectiveness remains even in the presence of a large amount of organic material.

The silver compositions are widely effective in vivo where the organic background is extremely high. Many other disinfecting agents are ineffective in the presence of a large amount of organic material and/or are too caustic or toxic to be used in vivo.

Get detailed scientific information on the U.S. Patent Website.
Buy Silver Shield at wholesale price.

How Does Colloidal Silver Work?

2009-09-29T15:26:00.001-04:00

It disables the enzyme that one-celled bacteria, viruses, and fungi need for oxygen metabolism. In the presence of silver, these pathogenic microbes suffocate.

In one powerful experiment, 50 gallons of raw sewage were pumped into a pool without any disinfectant. The E. coli count (a standard measure of contamination) was at 7,000 E. coli cells per milliliter of water. The water was exposed to silver electrodes and within three hours, all 50 gallons were free of E. coli.

Colloidal silver is an effective ally in the fight against over 650 disease-causing organisms. These include: bacteria (typhoid, dyptheria, certain types of food poisoning, and pneumonia); viruses (the common cold, influenza, and measles); protozoa (malaria, giardiasis, amebic dysentery); fungi (ringworm, thrush, candida albicans, and athlete's foot); rickettsiae (rocky mountain spotted fever and Q fever); and chlamydiae (infections of the eye, the genitals, and the respiratory system). There is no known microbe that colloidal silver does not destroy.

It turns out that silver ions are very important for the immune system. They supplement and support the T-cells in fighting foreign organisms, almost forming a second immune system. In research done with AIDS, it appears that silver both protects and defends T-cells, and does their work for them. There is also a correlation between occurrence of illness and the level of silver in the body; people who are ill generally register lower levels of silver in their body.

Besides suffocating unwanted invaders, colloidal silver also helps injured tissues grow back. It has been useful in cases of severe burns and broken bones. It reduces scar tissue and helps severe cuts and wounds heal faster.

In prolonged, very heavy doses, some colloidal silver compounds will leave deposits in the heavier skin folds, like the knuckles. This permanent gray coloring of the skin is called Argyria; it is correctable with laser treatment. Argyria is very rare and most often associated with products that use particles of silver which are too large to be flushed out of the body's system naturally.

As long as the silver particle size ranges from .005 to .015 microns in diameter, there should be no problem. Silver Shield meets these requirements.

Simple 1-2-3 of How Silver Shield Works

1) The silver oxide coating of the nano-particle kills bacteria by pulling away one of the electrons on the bacteria cell membrane, which contributes to the rupture of the membrane and ultimately the death of the bacteria cell.

2) The special nano-silver process creates an electro-magnetic charge. Bacteria, like a virus DNA, have incomplete segments of DNA that have abnormal electrical charges. This silver nano-particle is magnetically attracted to the virus and overpowers its DNA by causing the DNA to bind into a tight ball. This renders the virus incapable of reproducing.

3) The special silver process has a magnetic resonance which is destructive to bacteria and viruses. Dr. Ruston Roy, Penn State University, has found these nano-particles resonate at between 890-910 tetrahertz, which is the same frequency that most labs use to protect doorways and counters in a lab from bacterial and viral contamination.

Buy Silver Shield at wholesale price.

Silver vs. Antibiotics

2009-09-28T15:28:00.001-04:00

An antibiotic kills a half-dozen different disease organisms. But because the antibiotic attacks the bacteria directly, and because bacteria adapt very well, they mutate to over-come the antibiotic. So every time an antibiotic is used, it becomes less effective for the next time it is needed.

But silver kills over 650 disease causing organisms, and it can do so every time. No resistant strains develop with the use of silver. Researchers speculate that this is because silver does not attack the microbe directly like an antibiotic does. It decomposes the enzyme microorganisms rely on to breathe-they can't mutate to counterattack silver's approach.

Another problem with antibiotics is that they kill beneficial enzymes while attacking the bad ones; pharmaceutical antibiotics can't distinguish between good and bad enzymes. This is why the immune system is especially weak after a round of antibiotics, and why yeast infections are much more likely after taking antibiotics.

Silver, however, doesn't destroy beneficial enzymes because they are very different from the enzymes of single-celled life which silver targets. Silver is nontoxic. Also, colloidal silver doesn't interact or interfere with other medicine being, taken.

Finally, antibiotics only affect bacteria. Silver disables bacteria, viruses, fungi, and all other disease causing organisms.

Buy Silver Shield at wholesale price.

Virus Protection: What To Do

2009-09-27T10:50:00.003-04:00

Swine Flu Influenza Type A/H1N1 Protection
for Health Care Practitioners and Their Patients
by Gordon Pedersen Ph.D.

Influenza viruses are the respiratory viruses of greatest public health importance, particularly Influenza A (1). Every year 36,000 people die from Influenza making it the 6th leading cause of death in America (1). The CDC estimates that it would cost America $71 - 166 billion if we have an Influenza epidemic today.

Approximately 1 in every 1,000 swine flu patients dies from the infection. This is close to the same rate we have been seeing the past few years but antigenic drift and antigenic shift may create a new and fatal form of Influenza that humans have no immunity against (2).

Antigenic drift is a variation within the HN sub-type. Antigenic shift is a variation between different HN sub-types, changes in the Heamagluttinin (H) and Neuraminiadase (N) makes large portions of the population immunologically naïve on a regular basis (1). The problem with Type A is that it undergoes both antigenic drift and antigenic shift making it more dangerous and unpredictable (1). The World Health Organization declared the H1N1 Swine Flu a pandemic in June of 2009 (3).

The annual average U.S. winter epidemics affect 5% to 20% of the population. The CDC (1) reports the following pandemic death histories:

Health Care Practitioners Are At The Highest Risk

Doctors, nurses and other health care providers are at the highest risk of becoming infected with Influenza. Because doctors are exposed to the virus most frequently, it is significant to recognize the survivability of the Influenza virus in open environments.

Mammalian Influenza A survives 1 hour in mucous, while Avian Influenza survives 100 days in water, 200 days @ 63 degrees F, 1 day in feces and indefinitely when frozen. Influenza is easily transmitted from human to human as indicated in the following table:

Doctors have the obligation to protect themselves and their patients from the potentially pandemic Influenza viruses. This protection could come from many different sources including Vaccination, Hygiene, Anti viral drugs, Antibiotic drugs, Nutritional supplements, Air filters, Water purifiers, Masks, Topical gels and Silver Sol.

Past epidemics provide important insights into what might happen in the potential spread of the current Swine Flu (4-13). The most persistent viruses survive and the most diverse seem to go extinct within a few years (14, 15). This is most likely the result of strong host-mediated selection pressure, resulting in continual evolution at key antigenic sites, a process termed ‘antigenic drift’ (15, 16). This antigenic evolution is observed with major changes in antigenicity occurring periodically in patterns of approximately 3 years between episodes (17).

According to reports from the Army Medical records, (from the 1918 Spanish Flu, H1N1 epidemic) 24% of the people died from the virus and 76% died form a secondary bacterial infection that produced pneumonia in the lungs. There is a high probability that the swine flu will have similar death rates, and if this is the case, then preventing and treating the secondary bacterial infection will be as important if not more important. The conclusion is that the influenza virus will need to be treated by multiple or combination therapies crossing viral and bacterial lines.

Recommendations For Influenza Prevention and Treatment (1)

Hygiene

The CDC recommends washing the hands after any exposure because most influenza is transferred by hand contact. Masks and gloves can help but the mask must fit tightly with no leaks to be effective. A surgical mask helps protect the persons around the wearer, so if you have a fever, cough or sneeze, wear a surgical mask to protect the patients.

Antiviral Drugs

These drugs have the ability to destroy viruses but cannot be taken for an extended period of time. They produce side effects that mimic the flu making it difficult to diagnose the severity of the disease.

If taken for prevention, Tamiflu produces resistance. 18% of the influenza virus is resistant to Tamiflu already (1). It is suspected that the health care professionals who were taking it for four months as a preventive agent were the persons that developed resistance. This indicates that we cannot use the antiviral drugs for long periods of time.

In addition, some drugs cannot be used in children under 13 years of age (Tamiflu). Relenza cannot be used in children under one or in adults over 65. The antivirals must be given within 48 hours of the onset of illness or the virus will run its course.

Combine this with the fact that 76% of H1N1 subjects in the Spanish flu 1918, died from a bacterial infection that produced pneumonia and you have an incomplete solution to the influenza problem. Because Tamiflu has developed resistance Relenza may be a better choice as long as you monitor the bronchospasms.

Antibiotic Drugs

Antibiotic drugs provide no solution against the virus but can be very beneficial for pneumonia that develops later. A broad spectrum antibiotic should be used because there are numerous bacteria that can produce pneumonia. According to a Penn State publication, Silver Sol can be given with the antibiotics and produce up to a tenfold increase in antibiotic activity (18).

Nutritional Supplements

There are hundreds of supplements that can be of significant benefit for the immune system and even some that claim to have antiviral activity. The best proven choices for nutritional supplements come in the form of immune stimulants and wellness products. These include: immunity Vit C, B complex, folic acid, vit D (prevention) ginseng, Echinacea, garlic, probiotics, expectorants and silver sol.

Air Filters

CDC recommends one in every room. HEPA air filters use silver to inactivate viruses and can effectively kill 99% of all bacteria, and viruses in minutes.

Water Purifiers

Proper hygiene and a water purifier are recommended by the CDC because the influenza virus can survive 100 hours in water. Get one that has a silver filter that can actually destroy the virus. Carbon, filtration, reverse osmosis does not destroy or remove the virus.

Topical Disinfectants

Topical disinfectants are recommended by the CDC for use between each patient and can kill germs for 4-6 hours. Patients and health care professionals should use these 4 times a day or as needed. Silver so gel demonstrates effectiveness against some of the worst pathogens including: MRSA, VRE, Strep, and the other bacteria that cause pneumonia.

Silver Sol

Prescription drugs and vaccines treat and help prevent viral infection and disease but are not capable of totally controlling a dangerous new or novel virus (18). Nutritional supplements such as Vitamins, Minerals, Echinacea, Ginseng, Probiotics and many others have the ability to help boost immune function and improve natural defenses which results in some defense against disease causing viruses and the associated secondary infections.

Silver Sol provides proven prevention and treatment against viral and bacterial infections, while there is nothing else with such broad spectrum benefits (19). In addition, Silver Sol can be safely taken every day for prevention where it has been shown to provide protection against the very dangerous Bird flu H5N1.

The combination of antibiotics with Silver Sol has been shown to enhance antibiotic function by as much as ten fold due to the fact that Silver Sol kills the residual pathogens that the antibiotics cannot (19). Results of the combination of 19 different prescription antibiotics and Silver Sol demonstrate safe additive and/or synergistic benefits across 7 different pathogenic strains (Staphyloccocus, MRSA, E coli, Pseudomonas arugenosa, Salmonella and Streptococcus). The results of this combination therapy result in significant pathogenic destruction while helping to reduce bacterial resistance (19).

This can be attributed to the fact that Silver Sol does not produce resistance, nor does it destroy the beneficial intestinal probiotic bacteria (18).

Discussion

H1N1 is a serious threat to our health and way of life. The best way to treat it influenza is to prevent it. Prevention produces a problem is that drugs have serious side effects and cannot be used by the entire population and should not be used for long periods of time. The other problem is that approximately three fourths of the people who have died from H1N1 influenza have succumbed to a secondary bacterial infection in the lungs and no antiviral drug will treat this condition.

In order to control an epidemic, all types of treatment should be employed including prescription drugs, vitamins, mineral, herbs, proper hygiene, air filtration, water filtration and the proper use of diet and nutritional supplements, especially the newly patented, FDA approved Silver Sol technology.

Silver Sol destroys bacteria, viruses, and mold so it demonstrates broader spectrum of activity than any antibiotic or antiviral drug. It can be taken daily due the fact that it passes through the body unchanged, and can prevent viral infections, treat them and work synergistically with antibiotics to produce as much as a ten fold increase in activity against the bacteria that cause death in influenza.

It is evident that the newly patented EPA certified and FDA approved Silver Sol technology provides tremendous treatment options for prevention and combination therapies. Silver Sol gel can help stop viral spread on the most contagious areas like hands, nose, mouth and skin. It is sufficiently documented and proven to be considered to be a first line of defense against Influenza and a significant companion to antiviral and antibacterial drug regimens topically and orally.

References

1. Centers for Disease Control contributing Authors: Burke Squires (UTSW), Marc Gillespie (CSHL), Peter E'dustacio (CSHL), Adolfo Garcï¿½a-Sastre (MSSM).

2. CDC. Update: swine-origin influenza A (H1N1) virus---United States and other countries. MMWR 2009;58:421.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;361.

4. World Health Organization. Situation updates---influenza A (H1N1). Geneva, Switzerland: World Health Organization; 2009.

5. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937--43.

6. Laver WG, Webster RG. Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutination proteins. Virology. 1968;34:193-202.

7. Sleigh MJ, Both GW, Underwood PA, Bender VJ. Antigenic drift in the hemagglutinin of the Hong Kong influenza subtype: correlation of amino acid changes with alterations in viral antigenicity. J Virol. 1981;37:845-853.

8. Fitch WM, Leiter JMF, Li X, Palese P. Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci. 1991;88:4270-4272.

9. Bush RM, Fitch WM, Bender CA, Cox NJ. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol. 1999;16:1457-1465.

10. Rvachev LA. Computer modeling experiment on large-scale epidemic. Dokl USSR Acad Sci. 1968;2:294-296.

11. Longini IM, Fine PE, Thacker SB. Predicting the global spread of new infectious agents. Am J Epidemiol. 1986;123:383-391.

12. Bonabeau E, Toubiana L, Flahault A. The geographical spread of influenza. Proc Biol Sci. 1998;265:2421-2425.

13. Grais RF, Ellis JH, Glass GE. Assessing the impact of airline travel on the geographic spread of pandemic influenza. Eur J Epidemiol. 2003;19:1065-1072.

14. Viboud C, Bjørnstad ON, Smith DL, Simonsen L, Miller MA, et al. Synchrony, waves, and spatial hierarchies in the spread of influenza. Science. 2006;312:447-451.

15. Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science. 1986;232:980-982.

16. Fitch WM, Leiter JMF, Li X, Palese P. Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci. 1991;88:4270-4272.

17. Fitch WM, Bush RM, Bender CA, Cox NJ. Long term trends in the evolution of H(3) HA1 human influenza type A. Proc Natl Acad Sci. 1997;94:7712-7128.

18. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371-376.

19. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003;422:428-433.

20. Thompson WW, Shay DC, Weintraub E, Brammer L, Cox N, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.

21. Thompson WW, Shay DC, Weintraub E, Brammer L, Bridges CB, et al. Influenza- Associated hospitalizations in the United States. JAMA. 2004;292:1333-1340.

22. Ina Y, Gojobori N. Statistical analysis of nucleotide sequences of the hemagglutinin gene of human influenza A viruses. Proc Natl Acad Sci. 1994;91:8388-8392.

23. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Phil Trans R Soc Lond B. 2001;356:1861-1870.

24. Jenkins GM, Rambaut A, Pybus OG, Holmes EC. Rates of molecular evolution in NA viruses: a quantitative phylogenetic analysis. 2002;54:156-165.

25. Centers for Disease Control and Prevention. Update: influenza activity, "United States and worldwide, 2006-2007 and composition of the 2007" 2008 influenza vaccine. MMWR. 2007;56:789-794.

26. Roy, R. Ultradilute Material Research Innovations, Ag-aquasols with extradrdinary bactericidal properties: role of the system Ag-O-H2O. 2007 vol 11 no 1.

27. Pedersen, G., Effect of Prophylactic Treatment with ASAP - AGX-32 and ASAP Solutions on an Avian Influenza A (H5N1) Virus Infecrion in Mice.

28 Nelson Labs . Hepatitis B and Silver Sol.

29. De Souza. A., Mehta, D, Bactericidal activity of Combinations of Silver-Water Dispersion with 19 Antibiotics Against Seven Microbial Strains. Current Science, Vol 91, No 7, October 2006.

30. Leavitt, R, Pedersen G,. Resistance of Silver Sol and Bacteria: A Discussion, ABL, 2009.

31 Viridis BioPharma, Probiotic Bacteria and Silver Sol, 2007.

32. Laver WG, Webster RG. Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutination proteins. Virology. 1968;34:193-202.

33. Sleigh MJ, Both GW, Underwood PA, Bender VJ. Antigenic drift in the hemagglutinin of the Hong Kong influenza subtype: correlation of amino acid changes with alterations in viral antigenicity. J Virol. 1981;37:845-853.

34. Fitch WM, Leiter JMF, Li X, Palese P. Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci. 1991;88:4270-4272.

35. Bush RM, Fitch WM, Bender CA, Cox NJ. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol. 1999;16:1457-1465.

36. Rvachev LA. Computer modeling experiment on large-scale epidemic. Dokl USSR Acad Sci. 1968;2:294-296.

37. Longini IM, Fine PE, Thacker SB. Predicting the global spread of new infectious agents. Am J Epidemiol. 1986;123:383-391.

38. Bonabeau E, Toubiana L, Flahault A. The geographical spread of influenza. Proc Biol Sci. 1998;265:2421-2425.

39. Grais RF, Ellis JH, Glass GE. Assessing the impact of airline travel on the geographic spread of pandemic influenza. Eur J Epidemiol. 2003;19:1065-1072.

40. Viboud C, Bjørnstad ON, Smith DL, Simonsen L, Miller MA, et al. Synchrony, waves, and spatial hierarchies in the spread of influenza. Science. 2006;312:447-451.

41. Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science. 1986;232:980-982.

42. Fitch WM, Leiter JMF, Li X, Palese P. Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci. 1991;88:4270-4272.

43. Fitch WM, Bush RM, Bender CA, Cox NJ. Long term trends in the evolution of H(3) HA1 human influenza type A. Proc Natl Acad Sci. 1997;94:7712-7128.

44. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371-376.

45. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003;422:428-433.

6. Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science. 2006;314:1898-903.

47. Rambaut A, Pybus O, Nelson MI, Viboud C, Taubenberger JK, et al. The genomic and epidemiological dynamics of human influenza A virus. Nature April 16; [Epub ahead of print]

48. Lavenu A, Leruez-Ville M, Chaix ML, Boelle PY, Rogez S, Freymuth F, Hay A, Rouzioux C, Carrat F. Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. Epidemiol Infect. 2005:1-7.

49. Nelson MI, Simonsen L, Viboud C, Miller MA, Taylor J, et al. Stochastic processes are key determinants of the short-term evolution of influenza A virus. PLoS Pathog. 2006;2:e125. doi:10.1371/journal.ppat.0020125.

50. Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. PLoS Med. 2006;3:e89. doi:10.1371/journal.pmed.0030089.

51. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC. Phylogenetic analysis reveals the global migration of seasonal influenza A viruses. PLoS Pathog. 2007;3:e131. doi:10.1371/journal.ppat.0030131.

52. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science. 2008;320:340-346.

53. Holmes EC, Ghedin E, Miller N, Taylor J, Bao Y, et al. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol. 2005;3:e300. doi:10.1371/journal.pbio.0030300.

54. Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, et al. Multiple reassortment events in the evolutionary history of A/H1N1 influenza A virus since 1918. PLoS Pathog. 2008;4:e1000012. doi:10.1371/journal.ppat.1000012.

55. Nelson MI, Holmes EC. The evolution of epidemic influenza. Nat Rev Genet. 2007;8:196-205.

56. Thompson WW, Shay DC, Weintraub E, Brammer L, Cox N, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.

57. Thompson WW, Shay DC, Weintraub E, Brammer L, Bridges CB, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340.

58. Ina Y, Gojobori N. Statistical analysis of nucleotide sequences of the hemagglutinin gene of human influenza A viruses. Proc Natl Acad Sci. 1994;91:8388-8392.

59. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Phil Trans R Soc Lond B. 2001;356:1861-1870.

60. Jenkins GM, Rambaut A, Pybus OG, Holmes EC. Rates of molecular evolution in NA viruses: a quantitative phylogenetic analysis. 2002;54:156-165.

61. Centers for Disease Control and Prevention. Update: influenza activity "United States and worldwide, 2006-2007 and composition of the 2007" 2008 influenza vaccine. MMWR. 2007;56:789-794.

62. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165:265-272.

63 a b Osterholm, Michael T. (2005-05-05). "Preparing for the Next Pandemic". The New England Journal of Medicine 352 (18): 1839-1842. doi:10.1056/NEJMp058068. PMID 15872196.

64 a b c Drazen, Jeffrey M.; Cecil, Russell L.; Goldman, Lee; Bennett, J. Claude (2000). Cecil Textbook of Medicine (21st ed.). Philadelphia: W.B. Saunders.

65. Thelancetoncology, (February 2007). "Leading Edge: High stakes, high risks". Lancet Oncology (The Lancet) 8 (2): 85. doi:10.1016/S1470-2045(07)70004-9. PMID 17267317.

66 Coghlan A (2006-08-14). www.newscientist.com/article/dn9734-mystery-over-drug-trial-debacle-deepens-.html Mystery over drug trial debacle deepens". Health. New Scientist.

67 Ferrara, JL.; S. Abhyankar, DG. Gilliland (February 1993). "Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1". Transplant Proc. 2 (25): 1216-1217. PMID 8442093.

68 Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY (February 2005). "An interferon-gamma-related cytokine storm in SARS patients". Journal of Medical Virology 75 (2): 185-94. doi:10.1002/jmv.20255. PMID 15602737.

69 Haque A, Hober D, Kasper LH (October 2007). "Confronting potential influenza A (H5N1) pandemic with better vaccines". Emerging Infectious Diseases 13 (10): 1512-8. PMID 18258000.

70 Lacey M McNeil DG Jr (2009-04-24). "Fighting Deadly Flu, Mexico Shuts Schools". NYTimes.com.

71 a b "Interim Guidance for Clinicians on Identifying and Caring for Patients with Swine-origin Influenza A (H1N1) Virus Infection". Centers for Disease Control and Prevention (CDC). 2009-04-29.

72 a b Humphreys, IR; G Walzl, L Edwards, A Rae, S Hill, T Hussell (2003-10-20). "A critical role for OX40 in T cell-mediated immunopathology during lung viral infection". J Exp Med. 198 (8): 1237-1242. doi:10.1084/jem.20030351. PMID 14568982.

73 Bhattacharya S (2003-10-20). www.newscientist.com/article/dn4293 New flu drug calms the 'storm.' New Scientist.

74 OX-40 Clinical Trial details,

75 Genctoy, G; B Altun et al. (February 2005). "TNF alpha-308 genotype and renin-angiotensin system in hemodialysis patients: an effect on inflammatory cytokine levels?". Artif Organs 29 (2): 174-178. doi:10.1111/j.1525-1594.2005.29029.x. PMID 15670287.

76 Moldobaeva, A; EM Wagner (December 2003). "Angiotensin-converting enzyme activity in ovine bronchial vasculature". J Appl Physiol (Department of Medicine, Johns Hopkins University) 95 (6): 2278-2284. doi:10.1152/japplphysiol.00266.2003 (inactive 2009-04-29). PMID 15670287.

77 Shigehara, K; N Shijubo et al. (April 2003). "Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis". Clin Exp Immunol (Sapporo Medical University School of Medicine) 132 (1): 152-157. doi:10.1046/j.1365-2249.2003.02105.x. PMID 12653850.

78 Marshall, RP; P Gohlke et al. (January 2004). "Angiotensin II and the fibroproliferative response to acute lung injury". Am J Physiol Lung Cell Mol Physiol (Royal Free and University College London Medical School) 286 (1): 156-164. doi:10.1152/ajplung.00313.2002. PMID 12754187.

79 Wang, R; G Alam et al. (November 2000). "Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo". J Cell Physiol (The Cardiovascular Institute, Michael Reese Hospital and Medical Center) 185 (2): 253-259. doi:10.1002/1097-4652(200011)185:2<253::AID-JCP10>3.0.CO;2-#. PMID 11025447.

80 Das UN (May 2005). "Angiotensin-II behaves as an endogenous pro-inflammatory molecule". The Journal of the Association of Physicians of India 53: 472-6. PMID 16124358.

81 Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP (May 2008). "The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination". Annals of the Rheumatic Diseases 67 (5): 713-6. doi:10.1136/ard.2007.077552. PMID 17965123.

Buy Silver Shield at wholesale price.

What To Look For In Colloidal Silver

2009-09-26T15:22:00.001-04:00

The highest-grade colloidal silver is produced by the electro-colloidal method. Colloidal silver can be produced using a grind method or a chemical process, but these solutions are not nearly as safe or effective.

99.999% fine silver in particle sizes ranging from .005 to .015 microns should be used in a quantity of 3 to 5 parts per million (ppm). Silver gives a golden hue when reduced to that particle size, so your colloidal silver should ideally be a pale golden yellow.

Darker colors indicate the use of larger particles. The weight of these larger particles will counteract the electric charge, and they will collect at the bottom of the container. Colloidal silver which contains dregs is not a true colloid.

Watch for products that contain a stabilizer. Silver will remain suspended on its own in a true colloid. Look out for trace elements other than silver or for any added coloring. Your colloidal silver should be nothing but fine silver and deionized water.

If the product needs to be shaken or requires refrigeration, it is not a true colloid. Finally, remember that high concentrations of silver do not kill germs more effectively than the safe range of 35 ppm.

Nature's Sunshine Silver Shield Differences

• Most Uniform Particle Size
• Safest and most effective of all colloidal silver products on the market
• 1 teaspoon provides 70 mcg. of pure silver
• Free from heavy contamination: lead, cadmium, nickel and aluminum
• Tasteless and odorless
• Completely non-toxic (this is not true for many other products)

Buy Silver Shield at wholesale price.

Silver Shield Recipes

2009-09-23T15:57:00.001-04:00

Uses From Dr. Gordon Pederson, developer of Silver Shield Silver Sol product. Dr Pedersen claims we could take a maintenance dose for the next 258 years and would not become toxic with the Silver Sol Technology. There's no fear of argyria (graying of skin).

Hand Sanitizer
Put Silver Shield liquid in an atomizer bottle for purse or pocket, or carry Silver Shield Gel with you in a small bottle.

Strep Throat Gargle
Use 1 teaspoon Silver Shield and gargle for 6 minutes, then swallow. Repeat every two hours first day and then 2 times daily after.

Ear Health
2-3 drops in each ear, keeping ear upward for up to 10 minutes to allow silver access into the ear cavity. Use 2-3 times a day if necessary.

Eye Health
Use 2-3 Silver Shield drops in eyes for up to 6 minutes for optimal exposure. Can use 2-3 times per day.

Ultimate level of extreme use for such as Malaria or Lyme’s Disease - Adult
First day - 1 bottle (4 oz) sipped throughout day
Next 2 days - 1/2 bottle (2 oz) consumed each day
Next 4 days - 1/4 bottle (1 oz) consumed each day
Continue two weeks with 2 teaspoons twice a day. Total of 5 bottles.
For children, dose according to weight assuming above dosage is for 150 lbs.

Facial Toner
Mix 3 parts alcohol-free toner or witch hazel to 1 part Silver Shield. Shake before using. Spray on face before using makeup or before bedtime.

Facial Mask
Use your favorite dry powder mask and substitute 1 teaspoon Silver Shield liquid or gel for water in the reconstitution process.

Wound Management
Apply Silver Shield Gel several times a day

Vaginal Tampon
Purchase tampon and remove the individual paper wrapper. Holding the applicator upright, pour 1 oz. liquid Silver Shield down the applicator onto the tampon. Insert for 30 minutes, then remove.

Vaginal Douche
Lie on back. Pump 2 oz liquid Silver Shield into vagina and hold for 12 minutes, then release.

Fungal Nails
Use Silver Shield Gel topically and may benefit using liquid internally.

Gingivitis Mouthwash
Use 1 teaspoon Silver Shield 4x per day swishing for 6 minutes. Continue for 3 days. Reduce to 2x per day for 1 week and then once daily maintenance.

Household Use
Super disinfect cutting boards, kitchen table, bathroom and kitchen counters. After cleaning, spray a light mist of Silver Shield and let air dry.

Skin and Feet
Use Silver Shield Gel topically on skin, feet, burns, skin irritations, rashes, fungal infections, diaper rash, etc.

Voice Spray
Put Silver Shield into a small purse-size spray bottle and use up to 10 times daily with 1-4 sprays each time.

What Is Colloidal Silver?

2009-09-19T15:12:00.001-04:00

People have long known that silver can be used as a purifying and preserving agent. In ancient Greece and Rome, people used silver containers to keep liquids fresh. Early American pioneers put silver dollars in bottles of milk to prevent spoilage. Laboratory workers placed silver dimes in petri dishes to sterilize them.

Today, more than half of the world's airlines use silver water filters because they protect against waterborne diseases like dysentery. NASA uses a silver water-purification system in its space shuttles. Silver is sometimes used in place of chlorine to purify swimming pool water.

And since the turn of the century, people have been using silver in colloidal form as an antibiotic treatment. In fact, until 1938, colloidal silver was considered a mainstream antibiotic treatment. But production was costly with early technology, and so the use of colloidal silver died out.

Colloidal silver is a complicated name for a simple chemistry project. A colloidal system refers to superfine particles suspended in water. We all recognize silver as a precious metal. So with colloidal silver, tiny particles of silver are electro-colloidally suspended in deionized water. The silver particles and the water are dispersed within and bound to each other by an electric current. This means that each of the silver particles is given a positive charge so they repel each other and the water around them, leaving them suspended in the water. The silver particles are not dissolved, nor should they sink. They remain suspended in the solution, held there by the electric charge.

Buy Silver Shield at wholesale price.

Pathogens Tested and Killed

2009-09-13T19:45:00.001-04:00

Concentration necessary to kill is noted in parts per million.
Silver Shield concentration is 18 ppm.

Bacillary Dysentery - Shigella boydii (2.5 ppm)
Boils - Staphylococcus aureus (5 ppm)
Burn Infections - Pseudomonas aeruginosa (5 ppm)
Corneal Ulcers-Keratitis - Pseudomonas aeruginosa (5 ppm)
Dental Plaque - Streptococcus mutans (5 ppm)
Diarrhea (Bloody) - Shigella boydii (2.5 ppm)
Diarrhea - Escherichia coli (2.5 ppm)
Ear Infection - Haemophilus influenzae (1.25 ppm)
Ear Infection - Streptococcus pneumonie (2.5 ppm)
Enteric Fever - Salmonella tyhimurium (2.5 ppm)
Epiglottitis (In children) - Haemophilus influenzae (1.25 ppm)
Eye Infections - Staphylococcus aureus (5 ppm)
Food Poisoning - Salmonella arizona (5 ppm)
Food Poisoning - Salmonella tyhimurium (2.5 ppm)
Food Poisoning - Escherichia coli (2.5 ppm)
Endocarditis - Streptococcus faecalis (2.5 ppm)
Endocarditis - Streptococcus gordonii (5 ppm)
Impetigo - Staphylococcus aureus (1.25 ppm)
Meningitis - Haemophilus influenzae (1.25 ppm)
Meningitis - Enterobacter aerogenes (2.5 ppm)
Meningitis - Pseudomonas aeruginosa (5 ppm)
Meningitis - Streptococcus pneumonie (2.5 ppm)
Nosocomial Infections - Klebsiella pneumoniae (2.5 ppm)
Nosocomial Infections - Pseudomonas aeruginosa (5 ppm)
Nosocomial Infections - (From Streptococcus pyogenes hospitals) (2.5 ppm)
Osteomyelitis - Staphylococcus aureus (5 ppm)
Pneumonia - Staphylococcus aureus (5 ppm)
Pneumonia - Haemophilus influenzae (1.25 ppm)
Pneumonia - Pseudomonas aeruginosa (5 ppm)
Pneumonia - Streptococcus pneumonie (2.5 ppm)
Respiratory Tract Infections - Streptococcus pyogenes (1.25 ppm)
Respiratory Tract Infections - E. coli (2.5 ppm)
Respiratory Tract Infections - Klebsiella pneumoniae (2.5 ppm)
Scarlet Fever - Streptococcus pyogenes (1.25 ppm)
Septicemia - Enterobacter aerpyogenes (2.5 ppm)
Sinus Infections - Haemophilus influenzae (1.25 ppm)
Sinusitis - Streptococcus pneumonie (2.5 ppm)
Skin Infections - Staphylococcus aureus (5 ppm)
Skin Infections - Streptococcus pyogenes (1.25 ppm)
Strep Throat - Streptococcus pyogenes (1.25 ppm)
Suppurative Arthritis - Haemophilus influenzae (1.25 ppm)
Throat Infections - Haemophilus influenzae (1.25 ppm)
Tooth Decay - Streptococcus mutans (5 ppm)
Urethritis (Men) - Trichomonas vaginalis (10 ppm)
Urinary Tract Infections - E. coli (2.5 ppm)
Urinary Tract Infections - Pseudomonas aeruginosa (5 ppm)
Urinary Tract Infections - Streptococcus faecalis (2.5 ppm)
Urinary Tract Infections - Enterobacter aerpyogenes (2.5 ppm)
Vaginitis (Women) - Trichomonas vaginalis (10 ppm)
Wound Infections - Escherichia coli (2.5 ppm)
Wound Infections - Enterobacter aerpyogenes (2.5 ppm)
Wound Infections - Klebsiella pneumoniae (2.5 ppm)
Wound Infections - Pseudomonas aeruginosa (5 ppm)
Wound Infections - Streptococcus faecalis (2.5 ppm)
Yeast Infections - Candida albicans (10 ppm)

Read entire patent document and get detailed scientific information on the U.S. Patent Website.
Buy Silver Shield at wholesale price.

Patent Info - Aqua Sol Technology

2009-09-12T14:32:00.002-04:00

Information from Patent #7,135,195 for Silver Sol
(Silver Shield Aqua Sol Technology)

It is well known that certain preparations of silver have germicidal properties. Silver was employed as a germicide and an antibiotic before modern antibiotics were developed. In previous centuries, users would shave silver particles into their drinking water, or submerge whole silver pieces in the drinking water, for the purpose of ingesting the silver by drinking the water. It seems likely that the practice of eating with silver utensils (i.e., silverware) resulted from a belief in the healthful properties of silver.

There may be many reasons why administering silver suspended in solution would enhance an individual's health. It is possible that such a solution operates to inhibit the growth of bacteria, viruses, and other unwanted organisms, as well as eradicating such existing bacteria, viruses, and other organisms. It is also possible that a solution of silver can have an anti-inflammatory effect, sufficient to reduce symptoms of asthma.

The present invention describes the use of a silver composition in water to treat certain human ailments. An embodiment of the invention is a silver composition comprising small particles of silver which comprise an interior of metallic silver and an exterior of ionic silver which particles are suspended in water. A preferred embodiment of the invention is a silver composition comprising particles of silver wherein more than 50% of the number of particles are less than 0.015 micrometers in size and the particles are colloidally suspended in water.

Pathogens That Have Been Tested And Killed
(Concentration necessary to kill is noted in parts per million. Silver Shield concentration is 18 ppm.

Bacillary Dysentery - Shigella boydii (2.5 ppm)
Boils - Staphylococcus aureus (5 ppm)
Burn Infections - Pseudomonas aeruginosa (5 ppm)
Corneal Ulcers-Keratitis - Pseudomonas aeruginosa (5 ppm)
Dental Plaque - Streptococcus mutans (5 ppm)
Diarrhea (Bloody) - Shigella boydii (2.5 ppm)
Diarrhea - Escherichia coli (2.5 ppm)
Ear Infection - Haemophilus influenzae (1.25 ppm)
Ear Infection - Streptococcus pneumonie (2.5 ppm)
Enteric Fever - Salmonella tyhimurium (2.5 ppm)
Epiglottitis (In children) - Haemophilus influenzae (1.25 ppm)
Eye Infections - Staphylococcus aureus (5 ppm)
Food Poisoning - Salmonella arizona (5 ppm)
Food Poisoning - Salmonella tyhimurium (2.5 ppm)
Food Poisoning - Escherichia coli (2.5 ppm)
Endocarditis - Streptococcus faecalis (2.5 ppm)
Endocarditis - Streptococcus gordonii (5 ppm)
Impetigo - Staphylococcus aureus (1.25 ppm)
Meningitis - Haemophilus influenzae (1.25 ppm)
Meningitis - Enterobacter aerogenes (2.5 ppm)
Meningitis - Pseudomonas aeruginosa (5 ppm)
Meningitis - Streptococcus pneumonie (2.5 ppm)
Nosocomial Infections - Klebsiella pneumoniae (2.5 ppm)
Nosocomial Infections - Pseudomonas aeruginosa (5 ppm)
Nosocomial Infections - (From Streptococcus pyogenes hospitals) (2.5 ppm)
Osteomyelitis - Staphylococcus aureus (5 ppm)
Pneumonia - Staphylococcus aureus (5 ppm)
Pneumonia - Haemophilus influenzae (1.25 ppm)
Pneumonia - Pseudomonas aeruginosa (5 ppm)
Pneumonia - Streptococcus pneumonie (2.5 ppm)
Respiratory Tract Infections - Streptococcus pyogenes (1.25 ppm)
Respiratory Tract Infections - E. coli (2.5 ppm)
Respiratory Tract Infections - Klebsiella pneumoniae (2.5 ppm)
Scarlet Fever - Streptococcus pyogenes (1.25 ppm)
Septicemia - Enterobacter aerpyogenes (2.5 ppm)
Sinus Infections - Haemophilus influenzae (1.25 ppm)
Sinusitis - Streptococcus pneumonie (2.5 ppm)
Skin Infections - Staphylococcus aureus (5 ppm)
Skin Infections - Streptococcus pyogenes (1.25 ppm)
Strep Throat - Streptococcus pyogenes (1.25 ppm)
Suppurative Arthritis - Haemophilus influenzae (1.25 ppm)
Throat Infections - Haemophilus influenzae (1.25 ppm)
Tooth Decay - Streptococcus mutans (5 ppm)
Urethritis (Men) - Trichomonas vaginalis (10 ppm)
Urinary Tract Infections - E. coli (2.5 ppm)
Urinary Tract Infections - Pseudomonas aeruginosa (5 ppm)
Urinary Tract Infections - Streptococcus faecalis (2.5 ppm)
Urinary Tract Infections - Enterobacter aerpyogenes (2.5 ppm)
Vaginitis (Women) - Trichomonas vaginalis (10 ppm)
Wound Infections - Escherichia coli (2.5 ppm)
Wound Infections - Enterobacter aerpyogenes (2.5 ppm)
Wound Infections - Klebsiella pneumoniae (2.5 ppm)
Wound Infections - Pseudomonas aeruginosa (5 ppm)
Wound Infections - Streptococcus faecalis (2.5 ppm)
Yeast Infections - Candida albicans (10 ppm)

Read entire patent document and get detailed scientific information on the U.S. Patent Website.
Buy Silver Shield at wholesale price.

Malaria Project in Ghana

2009-09-08T14:37:00.001-04:00

The massive amount of research about Silver Shield includes its use for malaria. View a video about a clinic in Africa that has been using Silver Shield successfully against malaria in children and adults. Ghana Clinic Uses Silver Shield for Malaria.

Buy Silver Shield at wholesale price.

8 Reasons To Use Silver Shield

2009-09-06T19:36:00.001-04:00

1. Patented Technology
This new AquaSol technology has made Silver Shield more effective than the old colloidal or ionic silvers. It requires smaller amounts, is totally non-toxic, and extremely safe. Patent Info

2. Scientifically Supported
Many laboratory reports and research studies have documented Silver Shield's benefits. Scientists have found this new silver solution can destroy 99.9% of all bacteria, molds, fungus, viruses, and other pathogens. The die-off begins within the first 15 seconds. Research Studies

3. Super Flexible
Silver Shield can be used internally and topically and also within the external orifices, such as eyes, nose and ears. It can be used mixed with water as a non-toxic alternative for household cleaners, as an effective disinfectant, like bleach, only safer. Effectiveness of Use

4. Quick Kill Time
In just a few minutes Silver Shield has accomplished great things. Research shows that exposing pathogens to this substance for only 3-6 minutes will kill them. Pathogens Tested and Killed

5. Inexpensive
When you calculate the cost of doctor visits, time loss from work, the exposure to other sick people, and cost of medications, Silver Shield is a real bargain. Silver vs. Antibiotics

6. Emergency Preparedness
Silver Shield is inorganic with no chemicals or other additives, so it can be stored for years at a time when the possibilities of life threatening viruses are abundant. Several government agencies and organizations have recommended the use of colloidal silver as a potential agent to fight against bioterrorism. Silver Fights The Germ War

7. Extremely Safe
With all the research, testing and long-term uses documented, Silver Shield has been proven to be safe and effective for everyone, including children, the elderly and pets. How Does Silver Shield Work

8. Convenience of Gel
Ease of use is enhanced with Silver Shield being provided in a liquid and gel. The gel is very convenient for all skin and nail topical applications. How Does Silver Shield Work

Buy Silver Shield at Wholesale Prices

Silver Shield For Pets

2009-09-05T10:36:00.001-04:00

Colloidal silver has become a popular alternative treatment for many of pet owners health concerns for their animals. The immune system support spectrum that Silver Shield provides surpasses anything on the market. With all the research, testing and long-term uses documented, Silver Shield has been proven to be safe and effective for everyone, including children, the elderly and pets.

The Silver Sol technology is a patented process that provides great antimicrobial effective at even lower concentrations of use. It's non-toxic and safe because of the size and useability of its silver particles. This is one item with many uses that you can have in your natural medicine chest for your family and pets.

Uses for Pets

• Make a spray bottle of it with water (8 oz. water to 1/2 t. Silver Shield) to spray pet's coat, rubbing down into the skin. Can also be used on bedding to disinfect.

• Add to the drinking bowl for daily immune support and fresher breath.

• A drop in each eye or several drops in each ear will help with eye or ear infections.

• Use on wounds, cuts and skin issues. It's soothing and dries quickly, reducing inflammation and aiding in quicker healing time.

Read about more uses that can be adapted for pets.
Learn about How Silver Shield Works. Purchase Silver Shield at wholesale prices.

Comments and Experiences with Silver Shield

2008-10-21T16:55:00.000-04:00

Use the comment feature below to add your own experiences using Silver Shield. This is not to recommend use by anybody else, but offers a platform for those who want to share their personal use of Silver Shield liquid and gel.